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Objective: The PREVENT III (PIII) critical limb ischemia (CLI) risk score is a simple, published tool derived from the
PIII randomized clinical trial that can be used for estimating amputation-free survival (AFS) in CLI patients considered
for infrainguinal bypass (IB). The current study sought to validate this risk stratification model using data from the
prospectively collected Vascular Study Group of Northern New England (VSGNNE).
Method: We calculated the PIII CLI risk score for 1166 patients undergoing IB with autogenous vein by 59 surgeons at
11 hospitals between January 1, 2003, andDecember 31, 2007. Points (pts) were assigned to each patient for the presence
of dialysis (4 pts), tissue loss (3 pts), age >75 (2 pts), and coronary artery disease (CAD) (1 pt). Baseline hematocrit was
not included due to a large proportion of missing values. Total scores were used to stratify each patient into low-risk (<3
pts), med-risk (4-7 pts), and high-risk (>8 pts) categories. The Kaplan-Meier method was used to calculate AFS for the
three risk groups. Log-rank test was used for intergroup comparisons. To assess validation, comparison to the PIII
derivation and validation sets was performed.
Result: Stratification of the VSGNNE patients by risk category yielded three significantly different estimates for 1-year
AFS (86.4%, 74.0%, and 56.1%, for low-, med-, and high-risk groups). Intergroup comparison demonstrated precise
discrimination (P < .0001). For a given risk category (low, med, or high), the 1-year AFS estimates in the VSGNNE
dataset were consistent with those observed in the previously published PIII derivation set (85.9%, 73.0%, and 44.6%,
respectively), PIII validation set (87.7%, 63.7%, and 45.0%, respectively), and retrospective multicenter validation set
(86.3%, 70.1%, and 47.8%, respectively).
Conclusion: The PIII CLI risk score has now been both internally and externally validated by testing it against the
outcomes of 3286 CLI patients who underwent autogenous vein bypass at 94 institutions by a diverse array of physicians
(three independent cohorts of patients). This tool provides a simple and reliable method to risk stratify CLI patients being
considered for IB. At initial consultation, calculation of the PIII CLI risk score can reliably stratify patients according to
their risk of death or major amputation at 1 year. ( J Vasc Surg 2009;50:769-75.)Critical limb ischemia (CLI) is the most advanced form
of peripheral arterial disease and it is associated with a high
risk of cardiovascular events, including major limb loss,
myocardial infarction (MI), stroke, and death.1-4 The like-
lihood of death has been reported to be as high as 20%
within 6 months of CLI diagnosis and surpasses 50% at 5
years post-diagnosis.5,6 These high mortality rates exceed
those seen in any other pattern of occlusive disease includ-
ing patients with symptomatic coronary artery disease
(CAD)7,8 and reflect the severe diffuse atherosclerotic bur-
den associated with a diagnosis of CLI.
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doi:10.1016/j.jvs.2009.05.055Traditionally, open surgical bypass was the only effec-
tive treatment strategy for limb revascularization in patients
with CLI due to infrainguinal arterial occlusive disease.
However, over the last decade, the introduction and evo-
lution of endovascular procedures has significantly in-
creased treatment options.5,9 This change of treatment
paradigm has been driven by technological advances, and
by the desire of patients and physicians to reduce proce-
dural risk, albeit with potential trade-offs of inferior
durability and greater cost.5 In order to improve clinical
decision-making, precise risk stratification for patients
who present with CLI has therefore become increasingly
important.
The PREVENT III (PIII) CLI risk score is an easy-to-
use risk stratification model (Fig 1) developed to predict
amputation-free survival (AFS) in CLI patients undergoing
open infrainguinal surgical bypass.10 This prediction tool
was derived from a cohort of patients who underwent
autogenous vein bypass for CLI in the context of the PIII
randomized trial.11 The PIII CLI risk score was then
validated internally using the trial cohort, and externally
using a multicenter retrospective cohort of patients. How-
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ied in a clinical trial, and may not represent “real world”
community and academic vascular surgery practice. There-
fore, the objective of the current investigation was to utilize
the prospectively collected Vascular Study Group of North-
ern New England (VSGNNE) database12 to further vali-
date the PIII CLI risk score. This dataset presents a unique
opportunity to validate and assess the utility of the PIII CLI
risk score in a heterogeneous population of CLI patients
selected to undergo surgical revascularization.
METHODS
The Vascular Study Group of Northern New En-
gland (VSGNNE). The VSGNNE is a regional coopera-
tive quality improvement initiative that was developed in
2002 to prospectively collect data on outcomes in patients
undergoing vascular surgery. Eleven different teaching and
non-teaching hospitals with 59 vascular surgeons (aca-
demic and private) currently participate in this program by
reporting data into the registry. All data are self-reported
and sent to a central data repository were they are aggre-
gated and reviewed. Research analysts are blinded to pa-
tient, surgeon, and hospital identity. At the time of dis-
charge after the index operation, a perioperative data sheet
containing preoperative, intraoperative, and postoperative
Fig 1. Score card. PIII, PREVENT III;HCT, hematocrit; CAD,
coronary artery disease.data is completed and submitted to the VSGNNE. Simi-larly, at 1-year follow-up (approximate; mean follow-up for
the entire cohort was 307 days), an additional data sheet is
completed and submitted to the VSGNNE. On this form,
data pertaining to ambulation status, symptom status, pa-
tency, ankle-brachial index, bypass graft revisions, or am-
putations are recorded. A current version of the Social
Security Death Index and the 1-year follow-up data are
used to confirm survival status. Since the inception of the
study, a rigorous audit system has been employed which has
consistently demonstrated 99% accuracy in capturing the
procedures and their associated outcomes.12 Details relat-
ing to the VSGNNE study design have been published
previously,12 and are available at www.vsgnne.org.
For the purpose of this study, the VSGNNEdataset was
limited solely to patients who underwent autogenous vein
lower extremity bypass for CLI (defined as gangrene, non-
healing ischemic ulcer, or ischemic rest pain). In an attempt
to be broadly inclusive (and to maximize our ability to
assess generalizability), as long as a patient had an autoge-
nous vein infrainguinal bypass for the indication of CLI,
regardless of bypass configuration, the patient was included
for this study. The study cohort consisted of 1078 patients
undergoing 1166 infrainguinal bypass procedures between
January 1, 2003, and December 31, 2007.
The PREVENT III cohort. Details of the PIII trial
design have been described elsewhere,11 but relevant fea-
tures are briefly reviewed here. PIII was a prospective,
randomized, double-blinded, multicenter trial designed to
examine the efficacy of a novel pharmacologic agent (edi-
foligide) in preventing autogenous vein graft failure in
1404 patients who underwent infrainguinal vein bypass at
83 hospitals exclusively for the treatment of CLI.13 This
trial incorporated mandated duplex scan surveillance, inde-
pendent adjudication of endpoints by a clinical events
committee, and external contract research organization
monitoring all study data per industry standards. The in-
clusion criteria specified patients at least 18 years of age who
underwent infrainguinal bypass (IB) with autogenous vein
for CLI.
The PIII CLI risk score. Details of the derivation and
validation of this risk stratification model have previously
been published.10 In brief, the PIII risk score utilizes five
easily obtainable binary variables—dialysis-dependency,
presence of tissue loss, age 75 years, hematocrit 30%,
and a history of advanced CAD—to stratify patients with
CLI and surgically correctable infrainguinal disease into
three distinct categories of expected AFS. An individual
patient is given a point value based on each binary variable.
The total sum of points is then converted to a score which
places the patient in the low- (score 3), medium- (score
4-7), or high-risk (score 8) category. Based on this cate-
gory, the model predicts the likelihood of surviving 1 year
after surgery without undergoing amajor amputation (low-
risk  86%, medium-risk  73%, high-risk  45%).
Validation of the PIII CLI risk score using the
VSGNNE. The prediction rule for 1-year AFS was applied
to the VSGNNE dataset. Each patient in the VSGNNE
dataset was given a net score based on the relevant preop-
ial fem
remen
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dialysis-dependent  4 points, tissue loss (ulceration or
gangrene) 3 points, age75 2 points, and a history of
advanced CAD (history of MI or unstable angina)  1
point. Of note, the baseline hematocrit was not included in
the scoring because until 2007, this variable was not rou-
tinely collected as part of the VSGNNE dataset. Despite
this limitation, we intentionally decided to maintain the
PIII risk scoring system as originally described10 in order to
properly test the risk stratification ability in a “real world”
setting. Based on the total sum of points, each patient was
assigned to a PIII risk score category: low-risk (score 3),
medium-risk (score 4-7), and high-risk (score 8).
A Kaplan-Meier 1-year AFS rate estimate was calcu-
lated for each VSGNNE risk group. The resulting AFS rates
were compared with those obtained from the original PIII
derivation and validation sets.10
Additional endpoints. The PIII CLI risk score was
specifically designed to stratify patients according to the
AFS endpoint and, to date, its discriminative ability has
only been tested in this context. Using the identical meth-
odology described above for 1-year AFS, the discriminative
ability of the PIII risk score on the following additional
30-day outcomes was assessed: (1) major adverse cardiac
Table I. Patient characteristics in the PREVENT III (PIII
New England (VSGNNE) validation set
Characteristics
PIII derivati
n  953 (
DEMOGRAPHICS
Female 348 (36.5
Age 75 307 (32.2
African American 173 (18.2
MEDICATIONS
Statin 431 (45.2
Antiplatelet 759 (79.6
Beta-blocker 554 (58.1
RISK FACTORS
Tissue loss (ulcer or gangrene) 701 (73.6
History of advanced CAD 393 (41.2
Previous ipsilateral bypass 138 (14.5
Smoking (ever) 709 (74.6
Diabetes 610 (64.0
Hypertension 774 (81.2
High cholesterol 445 (46.7
Dialysis-dependent renal failure 105 (11.0
Ankle brachial index 0.3* 457 (73.2
Weight 75 kg 502 (53.5
SURGICAL CHARACTERISTICS
Proximal anastomosis site
CFA 464 (53.8
SFA 234 (27.1
Popliteal 165 (19.1
Distal anastomosis site
Popliteal 320 (34.5
Tibial 505 (54.4
Pedal 103 (11.1
Single segment GSV conduit 781 (82.0
CAD, Coronary artery disease; CFA, common femoral artery; SFA, superfic
*In the VSGNNE dataset, 567 patients were missing a baseline ABI measuevent (MACE: death orMI [troponin elevation beyond thenormal range or ST changes/new Q waves on electrocar-
diogram]); (2) limb salvage; and (3) death. Similarly, the
discriminative ability of the PIII risk score on the following
additional 1-year outcomes was assessed: (1) limb salvage;
(2) death; (3) primary patency; (4) primary assisted pa-
tency; (5) secondary patency; and (6) ability to ambulate
(defined as ambulation with or without assistance).
Statistical analysis. Perioperative events were defined
as occurring before hospital discharge after the index oper-
ation. Baseline characteristics were compared between
groups using Pearson 2 analysis for categorical variables
and t test for continuous variables. Time-to-event endpoint
analyses at 1 year were performed using the Kaplan-Meier
method and intergroup analyses were compared with the
log-rank test. All tests were considered statistically signifi-
cant at an alpha level of 0.05 (P  .05, two-tailed). All
analyses were performed using SAS version 9.1 (Cary, NC).
Data submission to the VSGNNE registry was indepen-
dently reviewed and approved by the institutional review
boards at all participating institutions.
RESULTS
The VSGNNE cohort included 1166 bypass proce-
dures for CLI accumulated from 11 different practice set-
rivation set and the Vascular Study Group of Northern
VSGNNE validation set
n  1166 (%) P value
385 (33.1) .095
443 (38.0) .006
8 (0.7) .0001
386 (66.3) .0001
883 (77.3) .288
494 (84.7) .0001
830 (71.2) .225
451 (38.7) .231
124 (10.6) .007
923 (79.4) .009
714 (61.2) .190
1022 (87.7) .0001
632 (54.3) .0005
115 (10.0) .456
182 (24.1) .0001
440 (37.7) .0001
708 (64.0) .0001
240 (21.7) .027
158 (14.3) .017
483 (41.2) .001
470 (40.3) .0001
205 (17.6) .0001
993 (85.3) .042
oral artery; GSV, great saphenous vein; ABI, ankle brachial index.
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)tings across northern New England. The estimated 1 year
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line patient demographics, medication usage, comorbidi-
ties, and surgical characteristics were markedly different
from the PIII cohort (Table I). Patients in the VSGNNE
group were significantly older (age 75; 38.0% vs 32.2%;
P  .006) and less likely to be African American (0.7% vs
18.2%; P  .0001). Cardioprotective medications, such as
statins (66.3% vs 45.2%; P  .0001) and beta-blockers
(84.7% vs 58.1%; P  .0001), were more frequently used
in the VSGNNE group. A previous ipsilateral bypass was
less common in the VSGNNE group (10.6% vs 14.5%; P
.007). Of the comorbidities examined, patients in the
VSGNNE group were more likely to have used tobacco
(79.4% vs 74.6%; P  .0009), have hypertension (87.7%
vs 81.2%; P  .0001), and have high cholesterol (54.3%
vs 46.7%; P  .0001). In the VSGNNE group, a smaller
proportion of patients underwent bypasses to the tibial
or pedal vessels (58.8% vs 65.5%; P  .0001).
Discrimination into three strata of risk. The integer
score assigned to each covariate was used to calculate each
individual patient’s risk score for 1 year AFS. The scores
ranged from 0 to 10 (median 3, interquartile range 2-5). As
shown in Table II, the 1-year Kaplan-Meier estimated AFS
rates associated with each risk category were significantly
different (P  .0001 for each comparison): 1-year AFS
86.4% in the low-risk group (50.7% of cohort), 1-year AFS
74.0% in the medium-risk group (43.1% of cohort), and
1-year AFS 56.1% in the high-risk group (6.2% of cohort)
(Fig 2).
Validation. The VSGNNE 1-year AFS rates calcu-
lated above using the PIII risk score stratification scheme
were compared to the previously published rates obtained
from the PIII derivation set (n  953), PIII validation set
(n  451), and the retrospective validation set (n  716).
The 1-year AFS rates for each risk category were similar
when compared between each dataset (Fig 3). In the low-
risk group (PIII risk score 3), the 1-year AFS rate was
86.4% compared to 85.9%, 87.7%, and 86.3% in the PIII
derivation set, PIII validation set, and retrospective multi-
center validation set, respectively. In the medium-risk
group (PIII risk score 4-7), the 1-year AFS rate was 74.0%
compared to 73.0%, 63.7%, and 70.1% in the PIII deriva-
tion set, PIII validation set, and retrospective validation set,
respectively. In the high-risk group (PIII risk score 8),
Table II. Observed probability of 1-year amputation-free
survival and the associated hazard ratios for death or
major amputation at 1 year, stratified by the PREVENT
III (PIII) critical limb ischemia (CLI) risk score
Risk
categories
Integer
score
Amputation-free
survival HR (95% CI) P value
Low 3 86.4 1.0 (ref) —
Medium 4-7 74.1 1.87 (1.40-2.50) .0001
High 8 56.1 3.48 (2.34-5.18) .0001
HR, Hazard ratio; CI, confidence interval.the 1-year AFS rate was 56.1% compared to 44.6%, 45.0%,and 47.8% in the PIII derivation set, PIII validation set, and
retrospective validation set, respectively.
Composition of each risk group (Fig 4). The entire
VSGNNE cohort was analyzed to determine the break-
down of patients in each risk group according to each
independent predictor. High-risk classification was as-
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High Risk ≥ 8 Points
Medium Risk 4-7 Points
Fig 2. Kaplan-Meier curves demonstrating amputation-free (AF)
survival stratified according to each patient’s calculated risk score
(Vascular Study Group of Northern New England [VSGNNE]
cohort).
Fig 3. Validation of the PREVENT III (PIII) critical limb isch-
emia (CLI) risk score in 4 different datasets (3286 patients)—PIII
derivation set, PIII validation set, retrospective validation set,
prospective Vascular Study Group of Northern New England
(VSGNNE) validation set. AF, Amputation-free.
Fig 4. Risk category breakdown by predictor (Vascular Study
Group of Northern New England [VSGNNE] cohort). CAD,
Coronary artery disease.signed to 62% of the patients on dialysis, 9% of the patients
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13% of the patients with CAD.
Additional endpoints. In the VSGNNE cohort, the
PIII CLI risk score was an effective tool for discriminating
three significant strata of risk when tested on the following
endpoints: perioperative MACE (P  .003), perioperative
mortality (P  .001), 1-year mortality (P  .0001), and
1-year ability to ambulate (P  .0001) (Fig 5). On the
contrary, the PIII CLI risk score was not an effective tool
for discriminating three distinct strata of risk with regards
to perioperative limb salvage (P .14), 1-year limb salvage
(P  .06), or any of the evaluated patency outcomes
(primary patency, P  .09; primary assisted patency, P 
.59; secondary patency, P  .45).
DISCUSSION
The PIII CLI risk score is a reliable and simple tool for
stratifying CLI patients selected to undergo bypass surgery
into low-, medium-, and high-risk categories. At the time
of a patient’s initial presentation, five easily obtainable
binary variables (dialysis-dependency, tissue loss, advanced
age, advanced CAD, and low hematocrit) can be used to
provide patients and providers with a valid estimate of the
likelihood of AFS at 1 year after surgical revascularization.
As a result, we believe that the PIII CLI risk score is a useful
clinical tool for surgical decision making.
This model’s performance was initially derived and
validated in a select population of patients who were par-
ticipants in a randomized trial.10 It was then further vali-
dated in a multicenter retrospective cohort assembled from
three different hospitals.10 The present validation study
builds on these previous reports by extending the overall
generalizability of this risk score. The strength of the
VSGNNE dataset stems from its enrollment base—more
than 50 different surgeons (private and academic) at 11
hospitals (community and university, ranging in size from
25 to nearly 600 beds)—which provides heterogeneity and
a depiction of “real world” practice patterns.12,14 Despite
this heterogeneity and a dramatically different patient co-
hort than the one fromwhich themodel was derived (Table
I), the 1-year AFS estimates for each risk category are
remarkably similar.
The decision to model 1-year AFS as the primary
endpoint for the PIII CLI risk score was a deliberate one.
When considering a patient with CLI for surgical bypass,
we feel that an estimate of the probability that the patient
will be alive at 1 year, with an intact index limb, is of
paramount importance. Nonetheless, other endpoints
clearly play an important role in the determination of the
optimal treatment for a patient with CLI. These include,
but are not limited to, quality of life and functional out-
comes.15-17 The PIII CLI risk score was not designed to
evaluate these endpoints. Ultimately, the PIII CLI risk
score provides an additional piece of information that will
complement other elements of clinical judgment to inform
appropriate treatment choices for individual patients.
Because endpoints other than 1-year AFS are of value,
we investigated the ability of the PIII CLI risk score toLow Risk ≤ 3 Points
High Risk ≥ 8 Points
Medium Risk 4-7 Points
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Fig 5. PREVENT III (PIII) critical limb ischemia (CLI) risk
score was an effective tool for discriminating three significant strata
of risk when tested on the following endpoints: perioperative
major adverse cardiac event (MACE) (a), perioperative and 1-year
mortality (b), and 1-year ability to ambulate (c).
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1-year endpoints (MACE, death, limb salvage, ability to
ambulate, and graft patency). Looking at these results in
aggregate, it is clear that the PIII CLI risk score is more
effective for predicting “systemic” events (MACE, death,
and ambulation) rather than graft-related events (limb sal-
vage and patency). This reflects the focus of the original risk
score, which was modeled on the endpoint of 1-year AFS,
and which, therefore, prioritized traditional systemic pre-
dictors (ie, dialysis)18 above traditional graft predictors (ie,
vein diameter).19
It should be noted that the baseline hematocrit variable
was not included in this validation study due to a large
proportion of missing values in the VSGNNE cohort (not
routinely collected in the VSGNNE cohort until 2007). In
order to preserve (and test) the model as it was originally
described in its published form, we did not impute values or
adjust for this missing parameter in any way. As a result, it is
possible that a number of patients received lower scores
than they would have received had they been included in
the other three datasets (any patient with a recorded base-
line hematocrit30 would have received two extra points).
Despite this limitation, the AFS estimates for each risk
group remained consistent across each dataset. This raises
three possible considerations: (1) the effect of anemia is not
as strong of a predictor as the other included variables and
it, therefore, may not be an integral component necessary
for AFS risk stratification; (2) the distribution of VSGNNE
patients with a low baseline hematocrit was similar, by
chance, to the distribution of PIII patients with a low
baseline hematocrit; or (3) only a minority of patients in the
VSGNNE cohort may have had a baseline hematocrit30
and, therefore, the absence of this variable did not have a
profound effect. Further experience using the PIII risk
index, with increased patient numbers, will help clarify
whether baseline hematocrit remains critical to generating a
precise risk estimate. This study seems to suggest that this
may not be the case.
In addition to playing a prominent role in clinical
decision-making by allowing practitioners and patients to
better understand the possible risks of open surgical bypass,
we believe that the PIII CLI risk score may also be useful
for quality improvement initiatives. Now that this model
has been extensively validated in three independent patient
populations, the expected 1-year AFS rates can be calcu-
lated for a given dataset and these estimates can then be
used to create specific risk-adjusted benchmarks for individ-
ual practitioners or centers. In the same way that that the
National Surgery Quality Improvement Program20,21 has
created observed to expected ratios for individual centers,
the PIII CLI risk score can be used to generate accurate
comparative outcomes for patients undergoing bypass for
CLI. With an enhanced awareness of risk-adjusted out-
comes at distinct centers, efforts could be directed at iden-
tifying individual factors and processes of care that contrib-
ute to these improved outcomes. Once identified, these
processes could be promoted and implemented elsewhere
in order to improve the overall quality of care for the CLIpopulation. Similar efforts have been applied successfully in
a variety of other disease states such as cancer,22 MI,23
CAD,24 and peripheral arterial disease.25
CONCLUSION
The PIII CLI risk score has now been tested against the
outcomes of 3286 CLI patients who underwent infraingui-
nal autogenous vein bypass at 94 institutions by a diverse
array of physicians (three independent patient cohorts).
This tool provides a simple and reliable method to risk
stratify CLI patients being considered for IB. At initial
consultation, patients with a 50% chance of death or major
amputation at 1 year can be identified. Future investigation
is necessary to determine whether this risk prediction tool is
also effective for CLI patients undergoing endovascular
therapy.
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Dr C. Healey (Portland, Me): I assume you didn’t look at
prosthetic bypass or nonautologous veins in the NNE group
because the PREVENT trial didn’t have those patients. But did
you have an opportunity to look at that? Do you think if you took
people who got nonautogenous bypasses, would their results be
even poorer and would that be another score to put into your
decision-making tree?
Dr Schanzer. That is an interesting question. In the initial
iteration of this study we did include patients that had undergone
prosthetic bypasses and inclusion of these patients did not have any
significant effect on the results presented here. The model still
discriminated extremely well and provided similar 1 year estimates
for amputation free survival. As we further refined the current
study design, we felt that if we included prosthetic bypasses the
validation cohort would not be an appropriate comparison group
since the derivation study included a totally autogenous cohort. So
in order to maintain a clean and coherent study design, we ex-
cluded patients with prosthetic bypasses. Nonetheless, the answer
to your question is that it did not seem to alter the results in any
meaningful way.
DrW.Moore (Los Angeles, Calif): Your data clearly show that
your scorecard does discriminate between low, medium and high
risk patients. My question is, how do you plan to use this informa-
tion? Because even in your high risk patients, you had about a 53%
amputation-free survival. I hope you don’t plan to withhold treat-
ment in those patients even though theymay have a high risk score.
Dr Schanzer. I’m glad you brought up this very important
point. This question is one that, as investigators, we have struggled
with because you are absolutely right and we absolutely do not
wish to give the message that every single high risk patient should
be denied a surgical bypass procedure.
We feel that the PIII risk score is one tool that can be used to
help inform decision-making but that every individual patient mustpatients, a 50% 1 year amputation free survival may be considered
reasonable in light of the alternative options available. In other
patients, a 50% 1 year amputation free survival may not be consid-
ered reasonable. AS a result, we do not think that it is appropriate
to use this risk score to institute any broad sweeping guidelines.
Furthermore, our group is working on other prediction models for
other important endpoints such as quality of life, functional status
(i.e. ambulation), and non-composite endpoints such as mortality
and limb salvage. Ultimately all of these are going to have to be
used in concert. Unfortunately, one cannot create a single uber
model that encompasses all of these very relevant endpoints. Your
message is well stated and worth repeating– not every high risk
patient should be denied a bypass.
Dr M. Adelman (New York, NY): I wonder if there were
certain subgroups within the major groups (for instance, high risk
group) where specific interventions led to a better amputation-free
survival. In other words, are we going to start to indicate care for
different subgroups based on this data, or do the numbers get too
small as you break the data in smaller and smaller subsets?
Dr Schanzer. In brief, we have not further stratified the
groups beyond low, medium, and high risk as shown here. More-
over, all of these patients underwent autogenous vein bypass
surgery and no other types of revascularization procedures were
included in this analysis.
I think ultimately what you’re alluding to is that, as vascular
surgeons, we need to work towards developing the ability to better
identify which subgroups of patients will benefit from which spe-
cific treatment modality. In my opinion, the big challenge ahead of
us is to learn how to discriminate patient populations prospec-
tively. As we all know, there is a role for surgical bypass, there is a
role for endovascular intervention, and there is a role for primary
amputation. We need to get better at understanding how to apply
these techniques to the appropriate patient populations.
